The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use
Use of apixaban resulted in slower progression of coronary atherosclerotic and calcified plaques compared to warfarin in AF patients, measured by CTA.
CME accredited course focussed on PCSK9 inhibitors as novel strategy to reduce LDL-C. Member registration (free) is needed to enroll in this course
Systematic screening in relatives of probands with FH and elevated Lp(a) yielded more new cases than opportunistic testing in relatives of those without elevated Lp(a), but both approaches may be useful.
Consuming a diet with red meat as the main protein source for 4 weeks results in substantial increases in gut-microbiota-produced TMAO levels, as compared with isocaloric white meat and non-meat diets.
In a retrospective cohort study, major modifiable atherosclerotic risk factors were highly prevalent among adults aged 18-44 years hospitalized for a first AMI. Except for dyslipidemia, prevalence rates of risk factors progressively increased over time.
Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.
Obstructive CAD and adverse coronary plaque characteristics on CTA were associated with increased risk for CHD death or non-fatal MI, but CAC score was the only significant predictor of CHD risk in a post-hoc analysis of the SCOT-HEART trial.
Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .
Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.
In an observational study, objectively measured short sleeping times and fragmented sleep were associated with an increased risk of subclinical atherosclerosis in middle-aged subjects.
In a subanalysis of the FOURIER trial, treatment with evolocumab in patients with higher baseline Lp(a) resulted in non-significant greater percent reduction and greater absolute reduction of coronary events, compared to those with low baseline Lp(a).